<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01962571</url>
  </required_header>
  <id_info>
    <org_study_id>P000053</org_study_id>
    <secondary_id>2013-002515-10</secondary_id>
    <secondary_id>DRKS00005298</secondary_id>
    <secondary_id>01KG1306</secondary_id>
    <nct_id>NCT01962571</nct_id>
  </id_info>
  <brief_title>Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial</brief_title>
  <acronym>TONE</acronym>
  <official_title>Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Eye Hospital, Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Eye Hospital, Freiburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial aims at preventing visual dysfunction and optic nerve degeneration
      associated with autoimmune optic neuritis by systemic i.v. administration of 33.000 IU
      erythropoietin over 3 days. The primary objective is to determine the efficacy of
      erythropoietin compared to placebo given as add-on to methylprednisolone as assessed by
      measurements of retinal nerve fibre layer thickness and low contrast visual acuity 6 months
      after acute optic neuritis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global retinal nerve fibre layer thickness (RNFLT-G)</measure>
    <time_frame>6 months</time_frame>
    <description>Determination of the efficacy of erythropoietin compared to placebo given as add-on to methylprednisolone (standard of care) as assessed by measurement of global retinal nerve fibre layer thickness (RNFLT-G) in the affected eye 6 months after randomisation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low contrast visual acuity (LCVA)</measure>
    <time_frame>6 months</time_frame>
    <description>Determination of the efficacy of erythropoietin compared to placebo given as add-on to methylprednisolone (standard of care) as assessed by measurement of low contrast visual acuity (LCVA) in the affected eye 6 months after randomisation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute values of the global retinal nerve fibre layer thickness</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal nerve fibre layer thickness in the papillomacular bundle</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal nerve fibre layer thickness in the temporal quadrant</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total macular volume</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast sensitivity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean visual field defect</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Latency [ms] and amplitude [µV] of visual evoked potentials (VEP)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS) score</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Determined by NEI-VFQ-25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Screening until end of study</time_frame>
    <description>Assessment of AEs / SAEs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Optic Neuritis</condition>
  <arm_group>
    <arm_group_label>Erythropoietin alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant human EPO (Epoetin alfa HEXAL®) will be given as an i.v. bolus injection on days 1, 2 and 3. The dosage per day will be 33.000 IU in accordance with previous trials.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>As matched placebo for this study, sterile normal saline (0.9% sodium chloride for i.v. administration) will be used. It will be given as a bolus injection in the same manner as EPO.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin alfa</intervention_name>
    <arm_group_label>Erythropoietin alfa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients eligible for inclusion in this trial must meet all of the following criteria:

          1. Written informed consent obtained according to international guidelines and local laws

          2. Male and female patients aged ≥ 18 to ≤ 50 years

          3. Patients with ON

          4. First symptoms of ON ≤ 10 days prior to the first administration of investigational
             product

          5. High contrast visual acuity (HCVA) of ≤ 0.5 (decimal system)

          6. Adequate OCT measurements available

        Patients eligible for this trial must not meet any of the following criteria:

          1. Patient without legal capacity who is unable to understand the nature, significance
             and consequences of the trial

          2. Simultaneous participation in another interventional trial which could interfere with
             this trial and/or participation in a clinical trial within the last 3 months before
             enrolment in this trial

          3. Refractive anomalies: Hyperopia &gt; 5 dpt, myopia &lt; -7 dpt, astigmatism &gt; 3 dpt

          4. Media opacity

          5. Severe papillitis

          6. Previous ON

          7. Any other optic nerve and retinal disease

          8. Pre-existing MS or any other neurological disease

          9. Congenital diseases:

               -  thrombophilia

               -  phenylketonuria

         10. Acquired diseases:

               -  autoimmune diseases,

               -  cardiovascular diseases,

               -  diabetes mellitus,

               -  uncontrolled hypertension (with blood pressure &gt; 140 / 90 mm Hg (cf. chapter
                  7.7.5)),

               -  any malignancy,

               -  epilepsy,

               -  known tuberculosis with ongoing or unknown activity,

               -  acute gastrointestinal ulceration within the last 3 months prior to
                  randomisation,

               -  acute viral, bacterial or fungal infection,

               -  known infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus, or
                  Hepatitis C Virus,

               -  history of colitis ulcerosa, diverticulitis, or acute enteroanastomosis,

               -  known osteoporosis,

               -  history of thromboembolic events,

               -  elevated haemoglobin level (&gt;17 g/dl in men or &gt;15 g/dl in women)

               -  polycythaemia

               -  any other significant illness potentially interfering with any trial assessment
                  or trial treatment

         11. Performing semi-professional or professional sporting activities or physical training

         12. Pre-treatment with corticosteroids in the last 30 days prior to the onset of optic
             neuritis

         13. Pre-treatment with EPO

         14. Known or persistent abuse of medication, drugs or alcohol

         15. Active immunization within 2 weeks prior to randomisation

         16. Significant surgery within 4 weeks prior to randomisation

         17. Blood donation or bloodletting within 4 weeks prior to screening

         18. Pre-treatment with immunosuppressive or immunomodulatory agents

         19. Persons who are in a relationship of dependence/employment with the sponsor or the
             investigator

             This section concerns only female patients who are able to have a child:

         20. Current or planned pregnancy; nursing period within 3 months from investigational
             product administration

         21. Unwillingness to use one of the following safe combination methods of contraception
             within 3 months from investigational product administration to achieve a PEARL index
             of &lt;1: female condom, diaphragm or coil, each used in combination with a spermicide;
             hormonal intra-uterine device or hormonal contraception in combination with a
             mechanical method of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolf A. Lagrèze, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye Hospital, Medical Center - University of Freiburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Center - University of Freiburg, Eye Hospital</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heidelberg University Hospital, Department of Neurooncology</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuebingen University Hospital</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Munich</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Klinikum rechts der Isar, Munich</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Goettingen</name>
      <address>
        <city>Goettingen</city>
        <state>Niedersachen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duesseldorf University Hospital</name>
      <address>
        <city>Duesseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center of the Johannes Gutenberg University Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.tone-studie.de</url>
    <description>Study information and useful links in German language</description>
  </link>
  <reference>
    <citation>Sühs KW, Hein K, Sättler MB, Görlitz A, Ciupka C, Scholz K, Käsmann-Kellner B, Papanagiotou P, Schäffler N, Restemeyer C, Bittersohl D, Hassenstein A, Seitz B, Reith W, Fassbender K, Hilgers R, Heesen C, Bähr M, Diem R. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol. 2012 Aug;72(2):199-210. doi: 10.1002/ana.23573.</citation>
    <PMID>22926853</PMID>
  </reference>
  <reference>
    <citation>Diem R, Molnar F, Beisse F, Gross N, Drüschler K, Heinrich SP, Joachimsen L, Rauer S, Pielen A, Sühs KW, Linker RA, Huchzermeyer C, Albrecht P, Hassenstein A, Aktas O, Guthoff T, Tonagel F, Kernstock C, Hartmann K, Kümpfel T, Hein K, van Oterendorp C, Grotejohann B, Ihorst G, Maurer J, Müller M, Volkmann M, Wildemann B, Platten M, Wick W, Heesen C, Schiefer U, Wolf S, Lagrèze WA. Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol. BMJ Open. 2016 Mar 1;6(3):e010956. doi: 10.1136/bmjopen-2015-010956.</citation>
    <PMID>26932144</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2013</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Eye Hospital, Freiburg</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Wolf Lagrèze</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Optic neuritis</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Clinically isolated syndrome</keyword>
  <keyword>Erythropoietin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

